Lin-jian Wang

Dr. Lin-jian Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
YWYangyang Wu
Yangyang Wu
YWYanan Wu
Yanan Wu
SXShuchou Xia
Shuchou Xia
HLHongkai Lian
Hongkai Lian
YLYongli Lou
Yongli Lou
LWLin-jian Wang
Lin-jian Wang
Glioblastoma multiforme (GBM), the most aggressive primary brain malignancy in adults, is characterized by extensive vascularization and resistance to conventional anti-angiogenic therapies. In this study, through comprehensive integrative analyses of bulk RNA-seq and single-cell RNA-seq data, we identify COL4A2 as a critical orchestrator of vascularization in GBM. Elevated COL4A2 not only promotes epithelial-mesenchymal transition (EMT) in glioma cells, but also increases vascularization in GBM. Multi-omics profiling and mechanistic investigations reveal that aberrant expression of the anti-pause enhancer JMJD6 mediates the upregulation of COL4A2 in GBM. Furthermore, we demonstrate that COL4A2 promotes GBM vascularization by activating PI3K-AKT and MAPK-ERK signaling through interaction with ITGA1/ITGB1 receptors on tumor-associated endothelial cells (TECs). Pharmacological inhibition of the COL4A2-ITGA1/ITGB1 axis with obtustatin attenuates pro-angiogenic signaling, suppresses vascularization, and prolongs survival in orthotopic GBM models. Collectively, our findings establish JMJD6-driven COL4A2-ITGA1/ITGB1 axis as a novel anti-angiogenic therapeutic vulnerability, offering a promising strategy to disrupt TEC-tumor symbiosis and impede GBM progression.

11 December 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
LWLin-jian Wang
Lin-jian Wang
YWYangyang Wu
Yangyang Wu
SXSha Xie
Sha Xie
HLHongkai Lian
Hongkai Lian
Background: Cerebral arteriovenous malformations (AVMs) are intricate vascular anomalies that disrupt normal cerebral blood flow, potentially leading to severe neurological complications. Although the pathology of AVMs is not fully understood, epigenetic mechanisms have been implicated in their formation.Methods: Transcriptional differences between cerebral AVMs and normal tissues were analyzed using RNA sequencing (RNA-seq), identifying IGF2BP2 as a key differentially expressed gene. Comprehensive bioinformatics analysis, integrating multi-omics data such as RNA-seq and methylated RNA immunoprecipitation sequencing (MeRIP-seq), was employed to identify the downstream target gene of IGF2BP2. The roles of specific genes in vascular development were assessed using endothelial cell cultures and zebrafish models.Results: Our analysis of RNA-seq data from cerebral AVMs and normal tissues identified IGF2BP2, a key N6-methyladenosine (m6A) reader, as significantly downregulated in cerebral AVMs. Functional studies showed that IGF2BP2 knockdown resulted in abnormal angiogenesis in endothelial cells and disrupted vascular development in zebrafish models. Mechanistically, IGF2BP2 regulates LGALS8 expression by modulating mRNA stability through m6A modification, and LGALS8 deficiency severely impairs angiogenesis in vitro and leads to cerebrovascular dysplasia in vivo.Conclusion: Our findings suggest that IGF2BP2, via m6A-dependent regulation of LGALS8, is crucial for vascular development and presents potential targets for therapeutic intervention in cerebral AVMs.

29 January 2026 in Life Sciences
Verified
Journal Article
Closed access
JMJieyu Ma
Jieyu Ma
LXLi Xu
Li Xu
NSNai Sun
Nai Sun
JSJianqiang Song
Jianqiang Song
JWJie Wang
Jie Wang
QSQiong Song
Qiong Song